This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by George, J. Articles by Shoenfeld, Y. Search for Related Content PubMed PubMed Citation Articles by George, J. Articles by Shoenfeld, Y. Pubmed/NCBI databases Substance via MeSH

(Circulation. 1998;98:1108-1115.)
© 1998 American Heart Association, Inc.

Basic Science Reports

Induction of Early Atherosclerosis in LDL-Receptor–Deficient Mice Immunized With ß₂-Glycoprotein I

Jacob George, MD; Arnon Afek, MD; Boris Gilburd, MD, PhD; Miri Blank, PhD; Yair Levy, MD; Anabel Aron-Maor, MD; Hana Levkovitz, BA; Aviv Shaish, PhD; Iris Goldberg, PhD; Juri Kopolovic, MD; Dror Harats, MD; ; Yehuda Shoenfeld, MD

From the Research Unit of Autoimmune Diseases, Department of Medicine B (J.G., B.G., M.B., Y.L., A.A.-M., Y.S.); the Institute of Pathology (A.A., I.G., J.K.); and the Institute of Lipid and Atherosclerosis Research (H.L., A.S., D.H.), Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Israel.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Immunization with ß₂-glycoprotein I (ß2GPI), the probable target of autoimmune anticardiolipin antibodies, results in experimental antiphospholipid syndrome in different mouse strains. The present study was undertaken to evaluate the effect of ß2GPI immunization on the progression of atherosclerosis.

Methods and Results—In the first experiment, 3 groups of LDL receptor–deficient (LDL-RD) mice (n=15 per group) were immunized with either ß2GPI or ovalbumin or were not immunized and were fed a chow diet for 12 weeks. In a second experiment, 3 groups of LDL-RD mice (n=10 per group) were immunized similarly and fed an atherogenic diet for 6 weeks. All ß2GPI-immunized mice developed high titers of anti-ß2GPI antibodies as well as a specific lymph node proliferation to ß2GPI. The average cholesterol levels did not differ between the mice fed similar diets, regardless of the immunization protocol. Atherosclerosis was enhanced in the ß2GPI-immunized mice (mean aortic lesion, 26 000±5700 µm²) in comparison with their ovalbumin-immunized (mean, 3000±1099 µm²; P<0.01) and nonimmunized (mean, 2250±700 µm²; P<0.01) littermates. The average lesion size in the ß2GPI-immunized mice fed an atherogenic diet (mean, 98 000±8305 µm²) was larger than the ovalbumin-immunized mice (mean, 81 250±12 933 µm²; P=NS) or the nonimmunized controls (mean, 75 625±7281 µm²; P=NS). The atherosclerotic plaques in the ß2GPI-immunized mice appeared to be more mature, and denser infiltration of CD4 lymphocytes was present in the subendothelium of the aortic sinuses from this group of mice.

Conclusions—The results of the present study provide the first direct evidence for the proatherogenic effect of ß2GPI immunization and establish a new model for immune-mediated atherosclerosis.

Key Words: atherosclerosis • glycoproteins • antibodies • lipoproteins

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
The antiphospholipid syndrome (APS) is characterized by a prothrombotic predisposition manifested by thromboembolic events, thrombocytopenia, recurrent fetal loss, and additional systemic phenomena.^{1 2} The syndrome is associated with high titers of anticardiolipin antibodies (aCLs), which have traditionally been suggested to target negatively charged phospholipids. Circumstantial data imply that patients with systemic lupus erythematosus (SLE) (a high proportion of whom have high titers of aCLs) are prone to develop premature atherosclerosis.^{3 4} However, the mechanisms underlying the proatherogenic predisposition are still unresolved.

The issue of target recognition by aCLs has been the subject of intensive research in recent years. Some authors suggested that aCLs bind native phospholipids,⁵ whereas others proposed that certain plasma cofactors, on binding to phospholipids, could allow for aCL attachment.^{6 7 8 9}

ß₂-Glycoprotein I (ß2GPI) is a 50-kD plasma protein that possesses several in vitro anticoagulant effects (eg, inhibition of prothrombinase activity, ADP-induced platelet aggregation, and factor Xa generation).¹⁰ This glycoprotein has recently been considered to be the target of autoimmune aCLs, which are sometimes referred to as anti-ß2GPI antibodies.^{11 12} Several authors have shown that immunization of mice¹³ and rabbits^{14 15} with ß2GPI results in the production of antibodies that bear similarities to human autoimmune aCLs. Moreover, it has been shown by us¹⁶ and others¹⁷ that immunization with ß2GPI leads to manifestations resembling human APS in mice or exacerbates the respective syndrome in susceptible MRL/++ mice.¹⁸

Macrophages and smooth muscle and endothelial cells play a major role in the development of atherosclerotic plaque.¹⁹ Foam cells (the early, reversible lesions composed of lipid-containing macrophages) gradually develop into complicated plaques during the progression of atherosclerosis.¹⁹ These sequential events are thought to be accelerated by oxidation of plasma lipids. Oxidized LDL (oxLDL) has attracted major interest in view of its various effects on different cellular components, attesting to its immunogenicity and probable causal effect on atherosclerosis progression.^{20 21}

Several mechanisms could associate aCLs with enhanced atherogenesis, taking into consideration the effects on the cellular components within a mature atherosclerotic plaque. aCL and anti-oxLDL antibodies were shown to be cross-reactive,^{22 23 24} and some suggest that aCLs actually target oxidized rather than native phospholipids.²⁵ Very recently, Hasunuma et al²⁶ showed that anti-ß2GPI antibodies enhance the in vitro uptake of oxLDL to macrophages (the candidate progenitors of foam cells), postulating that it could contribute to enhanced atherogenesis.

Endothelial cells are also essential to the development of atherosclerosis, possibly by a prior activation resulting in expression of adhesion molecules.¹⁹ aCLs as well as rabbit anti-ß2GPI antibodies have been demonstrated to bind and activate cultured human endothelial cells^{27 28} and could thus contribute to a proatherogenic state.

In the present study, we examined the effects ß2GPI immunization on the development of atherosclerosis. We have shown that LDL-receptor–deficient (LDL-RD) mice fed a chow diet and immunized with ß2GPI developed accelerated atherosclerosis.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals
Six-week-old female LDL-RD mice (hybrids of the C57BL/6J and 129Sv strains) were created by homologous recombination as described by Ishibashi et al.²⁹ The mice were obtained from the Jackson Laboratory (Bar Harbor, Me). We used LDL-RD mice for the experiments because this mouse maintains high cholesterol levels on a chow diet (levels similar to human values) and develops significant atherosclerosis only when fed a high-fat diet. Thus, the problem of the relative resistance of mice to atherosclerosis is overcome. BALB/c mice (8 weeks old) were purchased from the animal house of the Sackler School of Medicine, Tel Aviv University, Israel.

The LDL-RD and the BALB/c mice were either fed normal chow diet containing 4.5% fat by weight (0.02% cholesterol) or an atherogenic diet (Harlan, Teklad Premier Laboratory Diets) containing 1.25% cholesterol, 7.5% casein, and 0.5% (wt/wt) sodium cholate. The mice were maintained on 12-hour dark/12-hour light cycles and were allowed access to food and water ad libitum.

Antigens and Antibodies
Human ß2GPI was purified from the serum of a healthy adult as previously described by Gharavi et al.¹³ Mouse ß2GPI was purified from the serum of LDL-RD mice by a similar method.

For preparation of LDL and copper-oxidized LDL, blood for lipoprotein isolation was collected in EDTA (1 mg/mL) from mice after 12 hours of fasting. LDL (density, 1.019 to 1.063 g/L) was isolated from the plasma after density adjustment with KBr by preparative ultracentrifugation at 50 000 rpm for 22 hours with a type 50 rotor as previously described.³⁰ LDL preparations were washed by ultracentrifugation, dialyzed against 0.15 mol/L EDTA (pH 7.4), passed through an Acrodisc filter (0.22-µm pore size) to remove aggregates, and stored under nitrogen in the dark. Copper oxidation of LDL was performed by incubation of postdialyzed LDL (1 mg of protein/mL in EDTA-free PBS) with copper sulfate (10 µmol/L) for 24 hours at 37°C. Lipoprotein oxidation was confirmed by analysis of thiobarbituric acid–reactive substances (TBARS).³⁰

Recombinant heat shock protein (HSP)-65 was kindly provided by Dr M. Singh, Braunschweig, Germany.

Mouse monoclonal anti-ß2GPI antibodies Cof-21 and Cof-18 (both of which bind human and mouse ß2GPI)³¹ was a generous gift of Professor Takao Koike, Hokkaido University, Japan.

Rat monoclonal antibodies H129.19 (L3T4) anti-mouse CD4+ and S3-6.7 (Ly-2) anti-mouse CD8 were from PharMingen; MCA 497 (F4/80) anti-mouse macrophages were from Serotec.

Immunization Protocol
In the first experiment, LDL-RD mice (n=15) were immunized subcutaneously with a single dose of human ß2GPI (10 µg per mouse) emulsified in complete Freund's adjuvant (CFA). The 2 additional groups (15 mice each) either were immunized with ovalbumin (10 µg in CFA) or were not immunized. Fifteen BALB/c mice were immunized similarly with either ß2GPI or ovalbumin. All mice in the first experiment were given a normal chow diet and were killed 3 months after the immunization.

In the second experiment, 3 groups of LDL-RD mice (n=10 per group, 6 weeks old) were immunized with a regimen resembling the first experiment and fed an atherogenic diet for 6 weeks before they were killed.

Cholesterol Level Determinations
At the end of the experiment, 1 to 1.5 mL of blood was obtained by cardiac puncture; 1000 U/mL heparin was added to each sample. Total plasma cholesterol levels were determined by an automated enzymatic technique (Boehringer Mannheim).

Detection of Anti-ß2GPI Antibodies and Inhibition Studies
Anti-ß2GPI antibodies were detected by ELISA using either human or mouse ß2GPI (10 µg/mL) for coating and performed as previously described.¹⁶ Inhibition assays were performed to confirm the specificity of the mouse anti-ß2GPI antibodies and to check for their possible cross-reactivity with oxLDL. The concentration of serum from LDL-RD mice giving half of the maximal binding to ß2GPI was determined, and different inhibitors (at concentrations of 0 to 200 µg/mL) were used for inhibition (ie, oxLDL, LDL, human ß2GPI, BSA) with the anti-ß2GPI ELISA.

Detection of Mouse ß2GPI in Immune Complexes
For detection of mouse ß2GPI in immune complexes in sera from mice immunized with human ß2GPI, a dot blot assay was performed as previously described.³² Briefly, 10 µL of protein G–Sepharose beads were added to 20 µL of serum. After 30 minutes of incubation at room temperature, the beads were washed with PBS and resuspended in 10 µL of PBS. Five microliters of the suspension was applied to a BAS 85 nitrocellulose membrane (Schleicher and Schuell), and 5 minutes later, 2 µL of 0.1 mol/L glycine buffer (pH 2.5) was added to the beads. After blocking with 3% BSA and washings, the membranes were incubated for 1 hour with anti-ß2GPI biotinylated mouse monoclonal antibody (MAb). After additional washings (3 times, 15 minutes each), the membranes were transferred into a solution of streptavidin–horseradish peroxidase conjugate in PBS (1 : 25 000), and after extensive washing with PBS, a mixture of enhanced chemiluminescence detection reagents 1 and 2 (Amersham) were applied directly to the membranes. The membranes were exposed to x-ray film and after development were analyzed on a computing densitometer (model 300A, Molecular Dynamics). All sera were run in duplicate, and results of experiments were expressed as densitometry units.

Evaluation of Mouse ß2GPI Levels
For detection of mouse ß2GPI levels, we used capture ELISA. Ninety-six ELISA wells were coated with 10 µg of cof-18 (mouse MAb that binds human and mouse ß2GPI) in bicarbonate buffer overnight at 4°C and blocked with BSA. After washings, mouse sera from all experimental groups were added for 2 hours. After additional washings, 2 µg/mL of biotinylated cof-21 (mouse MAb that binds human and mouse ß2GPI) was added for 1 hour. Subsequently, the wells were incubated with alkaline phosphatase conjugated to avidin, and the reaction was developed with p-nitro-phenylphosphate. For quantification of mouse ß2GPI levels, the OD values were evaluated by construction of a standard curve with purified mouse ß2GPI. To confirm specificity, mouse ß2GPI was added to some wells containing mouse sera.

Detection of Anti-HSP-65 Antibodies
Antibodies to HSP-65 were detected with ELISA as previously described.³³ This assay was used to exclude the possibility that the immune response to HSP-65, which has been shown to be proatherogenic, influenced atherosclerosis progression

Detection of Anti-oxLDL Antibodies
ELISA plates (Nunc) were coated with either copper-oxLDL, native LDL (at a concentration of 5 µg/mL in PBS), or PBS overnight at 4°C. Serum fractions were diluted to 1:50, and ELISA was performed as previously described.³⁴ The assay was performed to rule out the possibility of cross-reactivity between anti-ß2GPI and anti-oxLDL antibodies, which may have affected lesion formation in the mice.

Proliferation Assays of Draining Lymph Node Lymphocytes From Mice Immunized With ß2GPI or Ovalbumin
Draining inguinal lymph nodes were collected from 4 ß2GPI- or ovalbumin-immunized mice killed 8 days after the primary immunization. The assays were performed as previously described,³⁵ with minor modifications. Briefly, 1x10⁶ cells/mL were incubated in triplicate for 72 hours in 0.2 mL of culture medium in microtiter wells in the presence or absence of various antigens: concanavalin A, human ß2GPI, mouse ß2GPI, HSP-65, oxLDL, and BSA in 4 different concentrations (20, 10, 5, and 2.5 µg/mL). Proliferation was measured by the incorporation of [³H]thymidine into DNA during the final 12 hours of incubation. The results were computed as stimulation index: the ratio of the mean cpm of the antigen to the mean background cpm obtained in the absence of the antigen. SDs were always <10% of the mean cpm.

Assessment of Atherosclerosis
Atherosclerotic fatty-streak lesions were quantified by calculating the lesion size in the aortic sinus as previously described,³⁶ with a few modifications. Briefly, the heart and upper section of the aorta were removed from the animals, and the peripheral fat was carefully cleaned. The upper section was embedded in OCT medium and frozen. Every other section (10 µm thick) throughout the aortic sinus (400 µm) was taken for analysis. The distal portion of the aortic sinus is recognized by the 3 valve cusps, which are the junctions of the aorta to the heart.

The extent of atherosclerosis was evaluated at the level of the aortic sinus. Processing and staining of the tissue with oil red O was carried out according to Paigen et al.³⁶ Lesion area was quantified by the method of Rubin et al.³⁷

Immunohistochemistry of Atherosclerotic Lesions
Immunohistochemical staining for CD4, CD8, and macrophages was done on 5-µm-thick frozen sections of the aortic sinus.³⁸ The sections were fixed for 4 minutes in methanol at -20°C followed by 10 minutes of incubation with ethanol at -20°C. The sections were then blocked with nonimmune goat serum for 15 minutes at room temperature followed by incubation with CAS blocking reagent for 30 minutes at room temperature. Subsequently, the rat anti-mouse CD4/CD8 MAbs were added for 1 hour at room temperature. After washings, affinity-purified biotinylated rabbit anti-rat IgG antibodies (Jackson) were added for 30 minutes at room temperature. After washings, the slides were incubated with 0.3% H₂O₂, followed by additional rinses and incubation with streptavidin-peroxidase conjugate for 30 minutes at room temperature. After washings, the slides were developed with 3-amino-9-ethylcarbonasole (AEC) substrate (Dako) for 15 minutes. Sections were counterstained with hematoxylin. Spleen sections were used as a positive control. Staining in the absence of first or second antibody was used as a negative control.

Statistical Analysis
The ANOVA test was used to compare values from the 3 experimental groups in each study. P<0.05 was accepted as statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Body Weight
In the first experiment, initial body weights for the LDL-RD were 23±2 g, and final body weights were 25±2 g. BALB/c mice weighed 19±2 g at the beginning and 21±2 g at the end of the experiment. In the second experiment, initial weights of the LDL-RD mice were 23±2 g, and final weights were 24±2 g. No differences in the average weight were detected between the study groups given similar diets. One mouse from the ß2GPI-immunized group and 2 mice immunized with ovalbumin died of infection during the experiment. Otherwise, none of the mice showed abnormalities in their general health.

Antibodies to ß2GPI, oxLDL, and HSP-65
All mice immunized with a single dose of human ß2GPI were found to develop high titers of antibodies against human and mouse ß2GPI, starting from 10 days after the immunization (Figure 1A and 1B, respectively). The high titers persisted until the mice were killed, 3 months after the immunization (Figure 2).

View larger version (19K): [in this window] [in a new window]   Figure 1. Binding of mouse sera to human and mouse ß2GPI. Plates were coated overnight with 5 µg/mL human (A) or mouse (B) ß2GPI (10 µg/mL). Sera from LDL-RD mouse immunized with ß2GPI, ovalbumin, or nonimmunized and BALB/c mice (taken at end of experiment) were tested in different dilutions. OVA indicates ovalbumin. Data represent average values taken from 10 mice per group.

View larger version (18K): [in this window] [in a new window]   Figure 2. Kinetics of anti-ß2GPI antibody titers during experiment. Mice were bled at monthly intervals and their sera tested by ELISA with human and mouse ß2GPI for coating. Sera were tested at 1:200 dilution; values are mean±SD of 10 mice in each study group.

No antibodies were found against oxLDL or HSP-65 (data not shown).

Specificity of Anti-ß2GPI Antibodies
The sera of the LDL-RD mice were inhibited in a dose-dependent manner by fluid-phase ß2GPI (inhibition of 91% of the binding to ß2GPI by a serum dilution of 1:200) but not with native LDL, oxLDL, or ovalbumin (Figure 3).

View larger version (13K): [in this window] [in a new window]   Figure 3. Inhibition of binding of sera from ß2GPI-immunized LDL-RD mice to ß2GPI. Fifty percent of maximal binding of anti-ß2GPI antibodies (from LDL-RD mice immunized with 10 µg ß2GPI) was determined by anti-ß2GPI ELISA. Subsequently, different concentration of inhibitors were added (oxLDL, native LDL, HSP-65, and human ß2GPI). Binding to ß2GPI was determined by anti-ß2GPI ELISA. Values are means from 10 LDL-RD mice.

Circulating Immune Complexes and ß2GPI Levels
Circulating immune complexes (CICs) containing mouse ß2GPI were determined from the sera of mice taken at the end point of the experiment. The levels of ß2GPI CICs were significantly higher in the chow diet–fed LDL-RD mice immunized with ß2GPI (mean, 2264±123 densitometry units [DU]) compared with ovalbumin-immunized (1401±156 DU, P<0.05) and with nonimmunized (1168±105 DU, P<0.05) mice (Figure 4).

View larger version (12K): [in this window] [in a new window]   Figure 4. CIC levels in LDL-RD mice fed a chow diet. A dot blot assay was used for detection of immune complexes containing mouse ß2GPI (as described in Methods) in sera of mice at end of experiment. Results are expressed as DU and represent average of 3 experiments. Each assay was performed on sera of 5 mice per group.

Levels of ß2GPI were similar in the 3 experimental groups fed chow diet and were in the range of 150 to 220 µg/mL (similar to the levels in humans).

Cholesterol Levels in the Studied Mice
No statistically significant differences were found with respect to the levels of cholesterol in the LDL-RD mice (ß2GPI-immunized, 219±25 mg/dL; ovalbumin-immunized, 228±25 mg/dL; and nonimmunized, 211±19 mg/dL). Similarly, no significant differences were noted between the atherogenic diet–fed mice: the mean cholesterol levels in the LDL-RD mice were 2348±56.6 mg/dL in the ß2GPI-immunized mice, 2434±44.4 mg/dL in the ovalbumin-immunized mice, and 2549±90 mg/dL in the nonimmunized mice. The cholesterol levels in the ß2GPI-immunized BALB/c mice were 78±12 mg/dL and in the ovalbumin-immunized mice, 81±11 mg/dL.

Proliferation of Lymph Node Lymphocytes on Exposure to ß2GPI, oxLDL, and HSP-65
Statistically significant stimulation indexes were observed only in the lymphocytes from the LDL-RD mice immunized with ß2GPI incubated with human ß2GPI (stimulation indexes in ß2GPI concentrations of 20, 10, 5, and 2.25 µg/mL were 2.49±0.156, 3.73±0.55, 3.51±0.55, and 3.83±0.625, respectively) (Figure 5). No reactivity of the lymphocytes was observed after in vitro exposure to mouse ß2GPI, oxLDL, HSP-65, or BSA in the LDL-RD mice immunized with ß2GPI.

View larger version (18K): [in this window] [in a new window]   Figure 5. Proliferation of lymphocytes from LDL-RD mice immunized with ß2GPI or ovalbumin. Draining inguinal lymph node lymphocytes were collected 8 days after primary immunization from 4 ß2GPI-immunized or ovalbumin-immunized LDL-RD mice. Lymphocytes were incubated with different antigens (human ß2GPI, mouse ß2GPI, HSP-65, oxLDL, and BSA) at different concentrations, and proliferative response was expressed as stimulation index. Hß2GPI indicates human ß2GPI; Mß2GPI, mouse ß2GPI. Values are means of 5 mice per group.

Extent of Aortic Sinus Atherosclerosis
Lesion size in the aortic sinus was most prominent in the LDL-RD mice immunized with ß2GPI (mean, 26 000±5700 µm²) compared with the LDL-RD mice immunized with ovalbumin (mean, 3000±1099 µm²; P<0.01) and with the nonimmunized mice (mean, 2250±700 µm²; P<0.01) (Figures 6 and 7). No significant differences were noted between the groups of atherogenic diet–fed mice: ß2GPI-immunized, 98 000±8305 µm²; ovalbumin-immunized, 81 250±12 933 µm²; and nonimmunized, 75 625±7281 µm². No atherosclerotic lesions were observed in the aortic sinuses of the BALB/c mice immunized with ß2GPI or ovalbumin.

View larger version (16K): [in this window] [in a new window]   Figure 6. Determination of atherosclerotic aortic lesion size. Aortic sinuses were cut and stained with oil red O. Assessment of plaque size was performed by an unbiased observer using a grid. Values are means of 15 mice per group.

View larger version (121K): [in this window] [in a new window]   Figure 7. Oil red O staining of atherosclerotic lesions. A, Average-size characteristic aortic sinus lesion from a chow diet–fed LDL-RD mouse immunized with ß2GPI; B, representative lesion from an ovalbumin-immunized LDL-RD mouse. Magnification x15.

Immunohistochemical Analysis of Atherosclerotic Lesions
The lesions of the chow-fed LDL-RD mice immunized with ß2GPI appeared to be more mature and contained significantly larger numbers of macrophages. Pronounced infiltration of the aortic sinus valvular and subendothelial intimal regions spanning the aortic sinus with CD4+ and CD8+ lymphocytes was noted in the LDL-RD mice immunized with ß2GPI (Figure 8). The lymphocytes found in the ß2GPI-immunized LDL-RD mice did not appear to reside only in the sites adjacent to the fatty streaks. Only a small number of CD4+ lymphocytes were evident in the aortic sinus of the LDL-RD mice immunized with ovalbumin or the control nonimmunized LDL-RD mice.

View larger version (119K): [in this window] [in a new window]   Figure 8. CD4 lymphocytes in aortic sinus of chow-fed ß2GPI-immunized LDL-RD mouse. Immunohistochemical staining with anti-CD4 antibodies (detailed in Methods) revealed dense infiltration of CD4 lymphocytes in subendothelial regions and valves of ß2GPI-immunized LDL-RD mice (characteristic photograph, A) compared with their ovalbumin-immunized littermates (B). Magnification x40.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Atherosclerosis entails the accumulation of lipids in the vessel walls, leading to their subsequent narrowing. In recent years, it has become apparent that the immune system plays a dominant role in mediating atherogenesis, although the exact mechanisms have not been characterized in detail.^{39 40} Several authors postulated that the atherosclerotic process could be triggered or enhanced by immunogens such as the HSP-60/65 or oxLDL.^{39 40} These candidate antigens were shown to promote humoral and cellular immune responses, which were suggested to account for their proatherogenic effects.

The rationale of the present study stems from several in vitro studies suggesting that aCLs could accelerate atherogenesis. Furthermore, clinical studies have shown that patients with SLE are at increased risk of developing premature atherosclerosis,^{3 4} although the exact relationship to anticardiolipin antibody positivity has not been determined. The endothelial cell–activating properties of aCLs^{27 28} and the enhanced in vitro uptake of oxLDL to macrophages induced by aCLs²⁶ could provide experimental support for this tentative hypothesis. Furthermore, several authors have shown that aCLs and anti-oxLDL antibodies are cross-reactive.^{22 23 24}

In the present study, we sought to demonstrate the effect of immunization with ß2GPI on the progression of atherosclerosis. Immunization of mice with human ß2GPI¹³ was previously shown to result in production of antibodies resembling autoimmune aCLs and with a clinical picture mimicking human APS.¹⁶ This model seemed appropriate for evaluating the effect of the anti-ß2GPI "response" on atherosclerosis.

The LDL-RD mice develop significant atherosclerosis only when fed a high-cholesterol diet, and they were chosen because their basal lipid levels are higher than those of control mice and thus the proatherogenic effect of ß2GPI immunization is more likely to be unmasked. As can be observed from the results, the LDL-RD mice immunized with human ß2GPI developed brisk and sustained immune response to the human ß2GPI. These antibodies also bound immobilized mouse ß2GPI, probably as a result of cross-reactivity. The LDL-RD mice developed significantly enhanced early atherosclerosis compared with their littermates immunized with ovalbumin. CD4+ lymphocytes were abundant in the valvular and subendothelial regions of the aortic sinus of the ß2GPI-immunized mice. However, their presence was not confined to areas of fatty streak lesions, and it cannot be determined whether these cells contributed to enhancement of atherosclerosis in these mice.

The second experiment was performed in LDL-RD mice fed an atherogenic diet. However, the differences in the extent of atherosclerosis when the mice were fed the high-fat diet did not reach statistical significance when the ß2GPI-immunized mice were compared with their ovalbumin-immunized littermates. The reason for the lack of difference when the atherogenic diet was fed could be that the effect of the high cholesterol levels on atherosclerosis development was so dominant that it made the effect of ß2GPI immunization negligible. Moreover, as shown recently, the lymphocyte density within the plaques of these mice seemed to diminish when they were fed a high-fat diet,⁴¹ making them more resistant to immunological modulation.

We immunized the mice with a single injection of 10 µg rather than the traditional multiple-injection protocol for 2 reasons. First, in preliminary studies, a single immunization was sufficient to induce high titers of anti-ß2GPI antibodies. Second, we wished to minimize the effects of different components found in adjuvants, some of which (ie, HSP-65) were shown to be associated with enhanced atherosclerosis.³⁹

By determining the levels of antibodies to HSP-65 and including a group of mice immunized with ovalbumin emulsified in CFA (which did not differ significantly from the nonimmunized group in the extent of atherosclerosis), we ruled out the possibility that the HSP-65 present in CFA was responsible for the accelerated atherosclerosis. The inhibition studies and lymphocyte proliferation assays excluded the possibility that immune response to ß2GPI was cross-reactive with oxLDL; cross-reactivity of aCLs with oxLDL could have affected the progression of atherosclerosis, because the latter antibodies are considered by some authors to be protective.^{42 43}

Several mechanisms could explain the enhanced atherosclerosis observed in the study: anti-ß2GPI antibodies have recently been shown to activate endothelial cells,^{27 28} and it is possible that recruitment of immunopotent cell results in accelerated atherosclerosis. Such immune-mediated recruitment could account for the abundance of the CD4+ and CD8+ lymphocytes as well as the accumulation of macrophages within the atherosclerotic plaques.

An additional mechanism that could account for the enhanced atherogenesis in the ß2GPI-immunized mice is an effect on macrophages. These latter cells were shown to accelerate the in vitro uptake of radiolabeled oxLDL in the presence of anti-ß2GPI antibodies.²⁶ This finding was explained by the association of anti-ß2GPI with ß2GPI, thus preventing the competition of the latter with oxLDL for the scavenger receptor–mediated binding to the macrophage. In this study, we have shown (Figure 1B) that the anti-human ß2GPI antibodies also bound mouse ß2GPI and could thus have influenced the uptake of lipids to resident macrophages, as was shown in the in vitro assays.²⁶ Moreover, ß2GPI possesses anticoagulant properties, and its "neutralization" by antibodies could contribute to a prothrombotic state, which could accelerate the atherosclerotic process.

The issue of binding of anti-human ß2GPI antibodies to native mouse ß2GPI in vivo was addressed by evaluation of the presence of immune complexes. Indeed, we have found higher levels of CICs containing mouse ß2GPI in the sera of the mice immunized with human ß2GPI, providing a possible explanation for the proatherogenic effect of the immunization. It should be mentioned in this respect that despite higher levels of CICs containing mouse ß2GPI, the serum levels of this anticoagulant molecule did not differ between the experimental groups, thus excluding the possibility that it may have affected atherosclerosis progression.

The control group in this experiment was immunized with ovalbumin. Use of an irrelevant protein for immunization might have been more appropriate in resolving ß2GPI specificity by these antibodies. However, this issue was addressed by evaluation of binding of the antibodies to immobilized or to circulating mouse ß2GPI (Figure 4).

NZWxBXSB F1 (W/B F1) male mice develop a spontaneous, SLE-like syndrome with production of several autoantibodies and CICs.⁴⁴ One of the features of the disease in these mice is a degenerative coronary vascular disease with myocardial infarction and thrombocytopenia. The production of antibodies to platelets and to ß2GPI/CL may play a pathogenic role in mediating the coronary vasculopathy, although lesions are not atherosclerotic but rather result from a prothrombotic state.

In conclusion, this study provides the first demonstration of a direct causal association between a cellular and a humoral immune response to ß2GPI and atherosclerosis progression. This observation is of particular interest because ß2GPI-binding antibodies formerly thought to invariably exist in APS patients are being increasingly reported in various infections.^{45 46} Because the association of infections with atherosclerosis has been raised by several authors (reviewed in References 47 and 48^{47 48} ), the occurrence of anti-ß2GPI antibodies could provide a possible explanation for this link.

	Acknowledgments

 
This study was supported by the Freda and Leon Schaller Grant for Research in Autoimmunity. We thank Professor Roald Nezlin (Department of Immunology, Weizmann Institute of Science, Rehovot Israel) for his help in determining circulating immune complexes.

	Footnotes

 
Reprint requests to Yehuda Shoenfeld, MD, Department of Medicine B, Sheba Medical Center, Tel-Hashomer 52621, Israel.

Received January 14, 1998; revision received April 20, 1998; accepted April 22, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet. 1993;342:341–344.[Medline] [Order article via Infotrieve]

2. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579–1587.[Abstract/Free Full Text]

3. Tsakraklides VG, Blieden IC, Edwards JE. Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus. Am Heart J. 1974;87:637–641.[Medline] [Order article via Infotrieve]

4. Jonsson H, Nived O, Sturfelt G. Outcome of systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore). 1989;68:141–150.[Medline] [Order article via Infotrieve]

5. Harris EN. Antiphospholipid antibodies. Br J Haematol. 1990;74:1–9.[Medline] [Order article via Infotrieve]

6. Galli M, Comfurius M, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335:1544–1547.[Medline] [Order article via Infotrieve]

7. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: ß2GPI (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120–4124.[Abstract/Free Full Text]

8. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin antibodies" recognize ß2-glycoprotein in the absence of phospholipids: importance of antigen density and bivalent binding. J Immunol. 1995;154:954–960.[Abstract]

9. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa D, Suzuki T, Sumida T, Yasuda T, Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992;148:3885–3891.[Abstract]

10. Kandia DA, Krilis SA. Beta2-glycoprotein I. Lupus. 1994;3:207–212.[Free Full Text]

11. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, Koike T. Antibodies to ß2GPI and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996;39:1466–1474.[Medline] [Order article via Infotrieve]

12. Alarcon-Segovia D, Cabral AR. The antiphospholipid/cofactor syndromes. J Rheumatol. 1996;23:1319–1322.[Medline] [Order article via Infotrieve]

13. Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid antibodies by immunization with ß2 glycoprotein I (apolipoprotein H). J Clin Invest. 1992;90:1105–1109.

14. Pierangeli SS, Harris EM. Induction of phospholipid binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol. 1993;93:269–272.[Medline] [Order article via Infotrieve]

15. Kouts S, Wang MX, Adelstein S, Krilis SA. Immunization of a rabbit with ß2-glycoprotein I induces charge dependent cross-reactive antibodies that bind phospholipids and have similar reactivity as autoimmune antiphospholipid antibodies. J Immunol. 1995;155:958–966.[Abstract]

16. Blank M, Faden D, Tincani A, Kopolovic J, Goldberg I, Gilburd B, Allegri F, Balestrieri G, Valesini G, Shoenfeld Y. Immunization with anticardiolipin cofactor (beta-2 glycoprotein-I) induces antiphospholipid syndrome in naive mice. J Autoimmunity. 1994;7:441–455.[Medline] [Order article via Infotrieve]

17. Garcia C, Kanbour Shakir A, Tang H, Espinoza LR, Gharavi AE. Induction of experimental antiphospholipid syndrome in PL/J mice following immunization with beta 2 glycoprotein I. Am J Repr Immunol. 1997;37:118–129.

18. Aron AL, Cuellar RL, Brey RL, Meceown S, Espinoza LR, Shoenfeld Y, Gharavi AE. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I. Clin Exp Immunol. 1995;101:78–84.[Medline] [Order article via Infotrieve]

19. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]

20. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924.[Medline] [Order article via Infotrieve]

21. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793–795.[Medline] [Order article via Infotrieve]

22. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;923–925:.

23. Mizutani H, Kurata Y, Kosugi S, Shiraga M, Kashiwagi H, Tomiyama Y, Kanakura Y, Good RA, Matsuzawa Y. Monoclonal anticardiolipin autoantibodies established from the (New Zealand White x BXSB)F1 mouse model for antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum. 1995;38:1382–1388.[Medline] [Order article via Infotrieve]

24. Vaarala O, Puurunen M, Lukka M, Alfthan G, Leirisalo-Repo M, Aho K, Palosuo T. Affinity purified cardiolipin binding antibodies show heterogeneity in their binding to oxidized low density lipoprotein. Clin Exp Immunol. 1996;104:269–274.[Medline] [Order article via Infotrieve]

25. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, Witztum JL. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest. 1996;98:815–825.[Medline] [Order article via Infotrieve]

26. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of ß2 glycoprotein I and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997;107:569–574.[Medline] [Order article via Infotrieve]

27. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96:2211–2219.

28. George J, Blank M, Levy Y, Meroni PL, Damianovich M, Tincani A, Shoenfeld Y. Differential effects of anti-ß2GPI antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation. 1998;97:900–906.[Abstract/Free Full Text]

29. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in LDL receptor knockout mice and its reversal by adenovirus mediated gene delivery. J Clin Invest. 1993;92:883–893.

30. George J, Blank M, Hojnik M, Bar-Meir E, Koike T, Matsuura E, Lorber M, Aviram M, Shoenfeld Y. Oxidized low density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome. Clin Exp Immunol. 1997;108:227–233.[Medline] [Order article via Infotrieve]

31. Igarashi M, Matsuura E, Igarashi Y, Nague H, Ichikawa K, Triplett DA, Koike T. Human ß2-glycoprotein I as an anticardiolipin cofactor determined using delegated mutants expressed by abaculovirus system. Blood. 1996;87:3262–3270.[Abstract/Free Full Text]

32. Nezlin R. Detection of the C3a complement component in commercial gamma globulins by dot blotting. J Immunol Methods. 1993;163:269–272.[Medline] [Order article via Infotrieve]

33. Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz B, Kaufman SHE, Wick G. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb. 1992;12:789–799.[Abstract/Free Full Text]

34. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Paliniski W, Witztum JL. Antibodies against oxidized LDL and the progression of carotid atherosclerosis. Lancet. 1992;339:883–887.[Medline] [Order article via Infotrieve]

35. Elias D, Markovits D, Reshef T, van der Zee R, Cohen IR. Induction and therapy in non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci U S A. 1990;87:1576–1580.[Abstract/Free Full Text]

36. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68:231–240.[Medline] [Order article via Infotrieve]

37. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature. 1991;353:265–267.[Medline] [Order article via Infotrieve]

38. Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL, Lusis AJ. Pathology of atheromatous lesions in inbred and genetically engineered mice: genetic determinations of arterial calcification. Arterioscler Thromb. 1994;14:1480–1497.[Abstract/Free Full Text]

39. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27–33.[Medline] [Order article via Infotrieve]

40. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5–11.[Medline] [Order article via Infotrieve]

41. Roselaar SE, Kakkanthu PX, Daugherty A. Lymphocyte population in atherosclerosis lesions of apoE -/- and LDL receptor -/- mice: decreasing density with disease progression. Arterioscler Thromb Vasc Biol. 1996;16:1013–1018.[Abstract/Free Full Text]

42. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821–825.[Abstract/Free Full Text]

43. Ameli SA, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yana J, Cercek B, Shah PK, Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 1996;16:1074–1079.[Abstract/Free Full Text]

44. Hashimoto Y, Kawamura M, Ichikawa K, Suzuki T, Sumida T, Yoshida S, Matsuura E, Ikehara S, Koike T. Anticardiolipin antibodies in NZWxBXSB F1 mice: a model of antiphospholipid syndrome. J Immunol. 1992;149:1063–1068.[Abstract]

45. Hojnik M, Gilburd B, Ziporen L, Blank M, Tomer Y, Scheinberg MA, Tincani A, Rosman B, Shoenfeld Y. Anticardiolipin antibodies in infections are heterogenous in their dependency in ß2 glycoprotein I: analysis of anticardiolipin in leprosy. Lupus. 1994;3:515–520.[Abstract/Free Full Text]

46. Louizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 1997;40:103–109.[Medline] [Order article via Infotrieve]

47. Cook PJ, Lip GYH. Infectious agents and atherosclerotic vascular disease. Q J Med. 1996;89:727–735.[Abstract/Free Full Text]

48. Libby P, Egan D, Scarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997;96:4095–4103.Both circumstantial and experimental data imply that autoimmune anti-cardiolipin antibodies found in the sera of antiphospholipid syndrome (APS) patients may be associated with atherothrombotic properties. In the present study, we wished to gain direct support for this hypothesis by evaluating the effect of ß₂-glycoprotein 1 (ß2GPI) immunization, previously shown to induce experimental APS, on atherosclerosis progression in LDL-RD mice. After a single active immunization with human ß2GPI, a pronounced and specific humoral and cellular response to the antigen ensued, concomitantly with the development of early atherosclerosis. Thus, we postulate that an immune response to ß2GPI has proatherogenic properties.[Free Full Text]

This article has been cited by other articles:

				R. Burioni, F. Canducci, D. Saita, M. Perotti, N. Mancini, D. De Marco, N. Clementi, A. Chieffo, M. Denaro, D. Cianflone, et al. Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques J. Immunol., August 15, 2009; 183(4): 2537 - 2544. [Abstract] [Full Text] [PDF]

				J. Ben-Shoshan, A. Afek, S. Maysel-Auslender, A. Barzelay, A. Rubinstein, G. Keren, and J. George HIF-1{alpha} Overexpression and Experimental Murine Atherosclerosis Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 665 - 670. [Abstract] [Full Text] [PDF]

				I. Gotsman, A. H. Sharpe, and A. H. Lichtman T-Cell Costimulation and Coinhibition in Atherosclerosis Circ. Res., November 21, 2008; 103(11): 1220 - 1231. [Abstract] [Full Text] [PDF]

				P. Liu, Y.-R. A. Yu, J. A. Spencer, A. E. Johnson, C. T. Vallanat, A. M. Fong, C. Patterson, and D. D. Patel CX3CR1 Deficiency Impairs Dendritic Cell Accumulation in Arterial Intima and Reduces Atherosclerotic Burden Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 243 - 250. [Abstract] [Full Text] [PDF]

				M. Franck, H. L. Staub, J. B. Petracco, G. L. Norman, A. J. Lassen, N. Schiavo, R. B. K. Borges, and C. A. von Muhlen Autoantibodies to the Atheroma Component Beta2-Glycoprotein I and Risk of Symptomatic Peripheral Artery Disease Angiology, July 1, 2007; 58(3): 295 - 302. [Abstract] [PDF]

				P. C. Dimayuga, X. Zhao, J. Yano, and K.-Y. Chyu Changes in immune responses to oxidized LDL epitopes during aging in hypercholesterolemic apoE(-/-) mice Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1644 - R1650. [Abstract] [Full Text] [PDF]

				A. Mor, G. Luboshits, D. Planer, G. Keren, and J. George Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes Eur. Heart J., November 1, 2006; 27(21): 2530 - 2537. [Abstract] [Full Text] [PDF]

				A.-K. L. Robertson and G. K Hansson T Cells in Atherogenesis: For Better or For Worse? Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2421 - 2432. [Abstract] [Full Text] [PDF]

				A. Yilmaz, J. Weber, I. Cicha, C. Stumpf, M. Klein, D. Raithel, W. G. Daniel, and C. D. Garlichs Decrease in Circulating Myeloid Dendritic Cell Precursors in Coronary Artery Disease J. Am. Coll. Cardiol., July 4, 2006; 48(1): 70 - 80. [Abstract] [Full Text] [PDF]

				A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]

				P R. Ames, C Tommasino, G Fossati, E Matsuura, A Margarita, A Saulino, L Lopez, G Scenna, and V Brancaccio Lymphocyte subpopulations and intima media thickness in primary antiphospholipd syndrome Lupus, October 1, 2005; 14(10): 809 - 813. [Abstract] [PDF]

				M A Baron, M A Khamashta, G R V Hughes, and D P D'Cruz Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data Ann Rheum Dis, January 1, 2005; 64(1): 144 - 146. [Abstract] [Full Text] [PDF]

				S. A. Robertson, C. T. Roberts, E. v. Beijering, K. Pensa, Y. Sheng, T. Shi, and S. A. Krilis Effect of {beta}2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice Mol. Hum. Reprod., June 1, 2004; 10(6): 409 - 416. [Abstract] [Full Text] [PDF]

				K. Kobayashi, M. Kishi, T. Atsumi, M. L. Bertolaccini, H. Makino, N. Sakairi, I. Yamamoto, T. Yasuda, M. A. Khamashta, G. R. V. Hughes, et al. Circulating oxidized LDL forms complexes with {beta}2-glycoprotein I: implication as an atherogenic autoantigen J. Lipid Res., April 1, 2003; 44(4): 716 - 726. [Abstract] [Full Text] [PDF]

				A. S. Major, S. Fazio, and M. F. Linton B-Lymphocyte Deficiency Increases Atherosclerosis in LDL Receptor-Null Mice Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1892 - 1898. [Abstract] [Full Text] [PDF]

				G. K. Hansson, P. Libby, U. Schonbeck, and Z.-Q. Yan Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis Circ. Res., August 23, 2002; 91(4): 281 - 291. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden European Association for the Study of Diabetes (EASD) 2001 Meeting Diabetes Care, July 1, 2002; 25(7): 1229 - 1236. [Full Text] [PDF]

				Y Sherer and Y Shoenfeld Atherosclerosis Ann Rheum Dis, February 1, 2002; 61(2): 97 - 99. [Abstract] [Full Text] [PDF]

				G. K. Hansson Immune Mechanisms in Atherosclerosis Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 1876 - 1890. [Abstract] [Full Text] [PDF]

				P E Spronk, E H Overbosch, and N H Schut Severe atherosclerotic changes, including aortic occlusion, associated with hyperhomocysteinaemia and antiphospholipid antibodies Ann Rheum Dis, July 1, 2001; 60(7): 699 - 701. [Abstract] [Full Text] [PDF]

				P A Gordon, J George, M A Khamashta, D Harats, G Hughes, and Y Shoenfeld Atherosclerosis and autoimmunity Lupus, April 1, 2001; 10(4): 249 - 252. [Abstract] [PDF]

				X. Zhou, G. Caligiuri, A. Hamsten, A. K. Lefvert, and G. K. Hansson LDL Immunization Induces T-Cell-Dependent Antibody Formation and Protection Against Atherosclerosis Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 108 - 114. [Abstract] [Full Text] [PDF]

				R. Wu, C. Lemne, U. de Faire, and J. Frostegard Antibodies to Lysophosphatidylcholine Are Decreased in Borderline Hypertension Hypertension, January 1, 2001; 37(1): 154 - 159. [Abstract] [Full Text] [PDF]

				P R J Ames, C Tommasino, J Alves, J D Morrow, L Iannaccone, G Fossati, S Caruso, F Caccavo, and V Brancaccio Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study Lupus, November 1, 2000; 9(9): 688 - 695. [Abstract] [PDF]

				E. Matsuura, J. Inagaki, H. Kasahara, D. Yamamoto, T. Atsumi, K. Kobayashi, K. Kaihara, D. Zhao, K. Ichikawa, A. Tsutsumi, et al. Proteolytic cleavage of {beta}2-glycoprotein I: reduction of antigenicity and the structural relationship Int. Immunol., August 1, 2000; 12(8): 1183 - 1192. [Abstract] [Full Text] [PDF]

				O Vaarala Antibodies to oxidised LDL Lupus, March 1, 2000; 9(3): 202 - 205. [Abstract] [PDF]

				D. Tanne, L. D'Olhaberriague, L. R. Schultz, L. Salowich-Palm, K. L. Sawaya, and S. R. Levine Anticardiolipin antibodies and their associations with cerebrovascular risk factors Neurology, April 1, 1999; 52(7): 1368 - 1368. [Abstract] [Full Text] [PDF]

				D. Harats, J. George, Y. Levy, M.A. Khamashta, G.R.V. Hughes, and Y. Shoenfeld Atheroma: links with antiphospholipid antibodies, Hughes syndrome and lupus QJM, January 1, 1999; 92(1): 57 - 59. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by George, J. Articles by Shoenfeld, Y. Search for Related Content PubMed PubMed Citation Articles by George, J. Articles by Shoenfeld, Y. Pubmed/NCBI databases Substance via MeSH